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ABSTRACT
Objective: To compare the effects of treatment of acute pain in the emergency department using
intravenous ketamine or intravenous morphine. Methods: A search was conducted in PubMed
using the terms (“low dose ketamine” OR “sub-dissociative dose ketamine”) AND “morphine”
AND (“emergency department” OR “ED”). The results were filtered for relevancy to our
research question. Results: All three studies demonstrated similar effectiveness between
morphine and ketamine in the first 30 minutes with similarly significant pain score reductions.
However, the analgesic effects of morphine consistently lasted longer than ketamine, and less
people in the morphine group required additional doses of medication. Adverse drug events
occurred at similar rates between the groups; although, different side effect profiles were
observed between the drugs, as expected. Conclusion: Ketamine does not appear to be a
replacement for morphine; however, ketamine shows potential to be a safe and effective
alternative option for treating acute pain in the ED. Further research is warranted to study the
safety and efficacy low-dose ketamine at higher doses infused over a longer duration or as usage
as an adjunct to morphine.
INTRODUCTION
Acute pain is the most common cause of emergency department (ED) visits in the United
States.1 Patients presenting to the ED with moderate to severe pain are commonly treated with
intravenous (IV) opioids. Morphine is mostly commonly used; however, a current shortage is
creating a demand for other options.2,3 Other IV opioids available for treating acute pain, such as
fentanyl and hydromorphone, are also in shortage according to the Food and Drug
Administration (FDA).3
Ketamine is a noncompetitive antagonist of N-methyl-D-aspartate receptors in the central
nervous system and at higher doses may also bind to opioid mu and sigma receptors.4 Ketamine
has been used as a dissociative general anesthetic for procedural sedation and intubation since
the 1970s.5 Positive attributes of ketamine for acute pain management include a very large
therapeutic window, rapid onset, and an adverse effect profile that is different from opioids.6,7
Most importantly, ketamine has an absence of significant respiratory complications; however,
elevated pulse and blood pressure, hallucinations, and dysphoria are common adverse effects.7
Low-dose IV ketamine is a potential candidate for safe and effective treatment of acute
pain management in the ED. Using ketamine will help increase medication diversity, which will
help prevent drug shortages by lessening the dependence on IV opioids. Using ketamine also
gives an additional benefit of providing a non-opioid option for patients. This study aims to
investigate ketamine as a safe and effective alternative to morphine for treatment of acute pain in
the ED.
PICO
Population: Adult hospitalized patients with acute pain
Intervention: IV Ketamine
Comparison: IV Morphine
Outcome: self-reported pain control and the occurrence of adverse reactions
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CLINICAL QUESTION
Can ketamine be used as a safe and effective alternative to morphine for the treatment of acute
pain in the ED?
METHODS
As outlined in Figure 1, an initial search of PubMed was performed using the search
terms (“low dose ketamine” OR “sub-dissociative dose ketamine”) AND “morphine” AND
(“emergency department” OR “ED”). This database search yielded 27 articles, none of which
were duplicates. We further screened these articles based on relevance to our study. For example,
if the article did not mention the use of ketamine for managing acute pain it was excluded, which
left us with 19 eligible articles. We then analyzed the remaining full-text articles to ensure they
were an appropriate match for our study. Articles were excluded if they did not compare
ketamine to morphine, if they focused on a single etiology of pain, or if they were meta-analyses.
Ultimately, three randomized controlled trials were chosen to include in this study. These articles
were chosen based on their comparison of morphine vs ketamine for treating acute pain, and
their use of numeric rating scale (NRS) pain scales to measure outcomes (Appendix 1).
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Figure 1. PRISMA flow diagram summarizing the article search process.
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RESULTS
Study 1
Low dose ketamine vs morphine for acute pain in the ED: A randomized controlled trial. Miller
et al.6
Objective
To compare the maximum change in NRS pain scores in patients receiving IV low-dose
ketamine (LDK) or IV morphine (MOR) for acute pain in the emergency department.
Study Design
The study was conducted in a tertiary, level one trauma center ED at San Antonio
Military Medical Center, with a patient population of uniformed military personnel (20%) and
civilians (80%). A convenience sample was obtained using standard enrollment protocol and
patients were selected based on criteria defined in Table 1.
Forty-five subjects were enrolled from March to November 2012 with similar
demographic variables, vital signs, and baseline NRS (7.1) pain scores. Patients were randomly
assigned to receive an initial dose of 0.3 mg/kg IV LDK (n=24) or 0.1 mg/kg IV MOR (n=21)
infused over 5 minutes. After 20 minutes, the patient was asked if another dose was needed. This
question was repeated every 20 minutes until 120 minutes had elapsed. Protocol allowed for a
second, equal dosage to be given as early as 20 minutes post-initial dose. Data collection was
stopped if the patient requested a third dose, underwent procedural sedations, or was discharged
from the ED. Midazolam treatment was allowed for agitation or emergence reactions, and
naloxone treatment was allowed for evidence of opioid overdose. Any other medication reactions
were treated per the provider’s discretion.
The primary outcome measurement was the maximum change on the verbal NRS pain
score as compared to the baseline score. Clinically meaningful change in the NRS score from
baseline was deemed to be 2 points between the treatment groups. The pain score was obtained
prior to drug administration and after administration at 5, 10, 20 minutes and then every 20
minutes thereafter up to 120 minutes. Secondary outcomes included levels of agitation or
sedation as measured by the Richmond Agitation-Sedation Scale (RASS), vital signs, adverse
events, and need for repeat dosing. Providers and nurses were surveyed after the patient
encounter to rate their satisfaction with the medication on a scale of 1 (very dissatisfied) to 5
(very satisfied). The outcomes were recorded and entered into a secured electronic database by a
blinded research nurse.
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Table 1. Inclusion and exclusion criteria for participation in study 1.
Inclusion Criteria

Exclusion criteria

18 to 59 years
Acute abdominal, flank, low back, or
extremity pain that the ED provider felt
warranted IV opioid treatment

Oxygen saturation < 95%
Systolic blood pressure < 90 mmHg or > 180
mmHg
Pulse rate < 50 or > 120 beats/min
Respiratory rate < 10 or > 30 respirations/min
AMS
Intoxication
Fibromyalgia or other chronic pain condition
requiring the use of opioids or tramadol as
outpatient
Ischemic heart disease, heart failure, or
unstable dysrhythmias
Use of an opioid or tramadol within 4 hours
prior to enrollment
Allergy to morphine or ketamine
Required pain medication immediately
Pregnant or breastfeeding
History of chronic oxygen-dependent
pulmonary disease
Hepatic cirrhosis
Dialysis-dependent
Presence of intracranial mass
History of psychosis
Weight < 45 kg or > 115 kg
Presence of acute ocular or head trauma

Study Results
The maximum change in NRS pain score from baseline in the MOR group was 5 at 100
minutes and 4.9 in the LDK group at 5 minutes. In the LDK group, there was an initial decrease
in pain scores followed by a rapid increase within the first 20 minutes, whereas the MOR group
experienced a steady trend of reduced pain over time (Table 2). A second dose was administered
in 54% of the ketamine group and only 38% in the morphine group. A third dose was requested
in 25% of the ketamine group and 14% in the morphine arm.
Secondary outcomes were similar between the groups. RASS scores varied within the
first 20 minutes after drug administration in both groups, but subsequent variation from baseline
was minimal. Ketamine caused a statistically significant increase in systolic blood pressure at 5
and 10 minutes from the morphine group, but no other differences were observed in vital signs.
Most notably, patients in the MOR group experienced more headache, drowsiness, and decreased
oxygen saturation, whereas the LDK group experienced more dysphoria and hallucinations.
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However, adverse event rates were similar across treatment groups. Neither Midazolam nor
naloxone was administered during the study and there were no dissociation or emergency
reactions.
The median provider satisfaction score was 4 (somewhat satisfied) for both LDK and
MOR groups, whereas the median nursing satisfaction score was 4 (somewhat satisfied) for LDK
and 5 (very satisfied) for the MOR group.
Table 2. Pain scores overtime in study 1.
Time
Morphine (95% CI)
T5
− 3 (− 3.9, − 2.1)
T10
− 3.4 (− 4.4, − 2.5)
T20
− 3.3 (− 4.4, − 2.2)
T40
− 4.5 (− 5.6, − 3.5)
T60
− 4.8 (− 5.8, − 3.8)
T80
− 4.4 (− 5.9, − 2.9)
T100
− 5 (− 6.6, − 3.5)
T120
− 5 (− 7.1, − 2.9)

Low-dose ketamine (95% CI)
− 4.9 (− 5.8, − 4)
− 4.3 (− 5.5, − 3.1)
− 3.2 (− 4.4, − 2.1)
− 3.7 (− 5.2, − 2.3)
− 3.5 (− 5.4, − 1.6)
− 3.9 (− 6.1, − 1.6)
− 4.1 (− 6.8, − 1.5)
− 3.6 (− 6.1, − 1)

Study Critique
Strengths include the study design and similar group characteristics. The study directly
compared morphine to ketamine for analgesia with a prospective, double-blinded randomized
control trial. The sample population had similar demographic variables, vital signs, and baseline
NRS pain scores, so confounding variables were limited.
The study had many limitations, such as small sample size with a possible
generalizability limitation, a non-standardized dose of ketamine for analgesia, and the use of
RASS in a non-validated setting. The sample size was approximately 20 patients per treatment
group enrolled at a military medical center. Results of the study may not be generalizable due to
the study location at a military medical center and sampling bias due to a convenience sample.
Due to the small sample, statistical analysis had to detect a two-point difference in maximum
change in NRS scores from baseline between the groups. Other authors have reported 1.3 as a
statistically significant change in NRS scores, so a greater difference in clinical effect between
the groups may be observed in a larger sample.8 A standardized dose of ketamine for analgesia is
not available, so the authors extrapolated data from other studies that suggested 0.3 mg/kg dosing
for adequate pain control without adverse neurologic effects.9 The RASS was used to measure
sedation and agitation. RASS is standardly used in the setting of the intensive care unit but not in
the ED, so the reliability and validity of this scale has not been established in the sample
population of this study.
Study 2
Acute pain management in emergency department, low dose ketamine versus morphine, a
randomized clinical trial. Mahshidfar et al.7
Objective
To compare analgesic effects of low dose ketamine versus morphine in trauma patients
presenting to the ED.
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Study Design
A double-blinded randomized clinical trial was conducted in two university teaching
hospital EDs in Tehran, Iran. Participants in this study were trauma patients aged 18 to 70 years
old who were referred to the ED with a musculoskeletal pain score of at least 5 on a standard
NRS. Other inclusion and exclusion criteria are summarized in Table 3.
From September 2014 to September 2015, 332 eligible participants were enrolled, but 32
patients were excluded from analysis due to study refusal, patient requesting morphine or
ketamine only, incomplete data, or disrespect to the study protocol. There was minimal
difference between the groups’ demographic characteristics, vital signs, or baseline pain scores.
Participants were randomly assigned into IV LDK (0.2 mg/kg) or IV MOR (0.1 mg/kg) treatment
groups equally using block randomization. Pain score, vital signs, and side effects were
measured at 0, 15, 30, 45, and 60 minutes after the drug was administered. Adequate pain
reduction was defined as a decrease in NRS pain score equal to 3 or more. If there was
insufficient pain reduction, 3 mg of IV morphine was injected every 5 minutes as a rescue
analgesic. Patient satisfaction was asked one hour after drug injection on a 5-point scale; a
response of 4 or 5 were defined as reaching proper analgesic effect.
The primary outcome measured in this study was change in NRS pain score as compared
to baseline over time. Other outcomes measured were changes in vital signs, development of
adverse effects, and patient satisfaction. The medication was administered by a blinded nurse,
but the study did not clearly state the outcome recorder.
Table 3. Inclusion and exclusion criteria for participation in study 2.
Inclusion Criteria

Exclusion Criteria

18 to 70 years old
Trauma patients presenting to ED
Rated pain at 5 or more on standard 0-10 NRS

Unstable vital signs
Head trauma
Glasgow coma scale < 15
Opiate user
Psychiatric or cardiac problem
Hypersensitivity to ketamine or morphine
Pregnancy
Breastfeeding
Renal or hepatic insufficiency
Upper respiratory infection
Patient requesting morphine or ketamine only

Study Results
The average baseline NRS pain score was 8.1 in the ketamine group and 8.4 in the
morphine group. There was a statistically significant reduction in pain scores at 15 minutes in
both groups with no significant difference between the groups. Subsequently at 30, 45, and 60
minutes, the morphine group had statistically significant lower pain scores than the ketamine
group (Table 4).
No life-threatening adverse effects were observed in either group. The morphine group
experienced a statistically significant higher incidence of flushing and decreased oxygen
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saturation below 90%. Other minor adverse effects were observed with equal incidence between
the groups such as nausea, dizziness, and mood changes. A higher score rate of patient
satisfaction was reported in the morphine group one hour after administration.
Table 4. Pain trends overtime in study 2.
Time (min)

Group

P Value

Ketamine

Morphine

0

8.1±1.1

8.4±0.9

0.15

15

4.1±2.8

4.0±2.5

0.23

30

4.5±3.1

3.8±3.0

0.01*

45

4.8±3.2

3.4±3.1

< 0.001*

60

4.9±3.3

3.2±2.9

< 0.001*

*P Values with statistical significance.
Study Critique
Strengths include the design, large sample size, and similar group demographics. The
study directly compared morphine to ketamine for analgesia with a double-blinded, randomized
controlled trial. This study has a large sample size since patients were enrolled from two large
teaching hospitals. Confounding variables were reduced due to similar patient demographics
between the groups.
Alternatively, limitations of the study were a potential for unblinding and limited
generalizability. There was a potential for unblinding due to the specific adverse reactions
associated with each medication. Extrapolation of the results to patients in the United States may
be problematic due to cultural or medical practice differences in Iran.
Study 3
Intravenous subdissociative-dose ketamine versus morphine for analgesia in the emergency
department: A randomized controlled trial. Motov et al.10
Objective
To compare the analgesic efficacy and safety of IV subdissociative-dose ketamine versus
morphine for acute pain in ED patients.
Study Design
The study was conducted in a 711-bed community teaching hospital as a prospective,
double-blinded, randomized control trial. Participants were 18 to 55 years old who presented to
the ED with acute abdominal, flank, back, or musculoskeletal pain rated at least 5 on a standard
NRS. Other inclusion and exclusion criteria are summarized in Table 5.
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Between June 2013 to May 2014, 90 participants were enrolled through convenience
sampling. The groups were similar regarding demographic characteristics, baseline vital signs,
pain scores, and chief complaint. Block randomization was utilized to equally divide participants
into treatment groups IV MOR (0.1 mg/kg) or IV LDK (0.3 mg/kg). Pain scores, vital signs, and
adverse effects were recorded at 15, 30, 60, 90, and 120 minutes after drug administration. If the
patient reported a pain NRS score of 5 or more and requested additional pain relief, 1 µg/kg of
fentanyl was utilized for rescue analgesia.
The primary outcome was comparative NRS pain score reduction after 30 minutes
between the treatment groups. Clinically meaningful change in the NRS score of acute pain in
the ED was deemed to be 1.3 between the treatment groups as evidenced by other studies.8 Other
outcomes analyzed were fentanyl rescue at 30 or 60 minutes, vital signs, and adverse reactions.
Outcomes were measured by a blinded provider then recorded by the blinded data-collection
team. The ED pharmacist, research manager, and statistician were not blinded.
Table 5. Inclusion and exclusion criteria for participation in study 3.
Inclusion Criteria

Exclusion Criteria

18 to 55 years old
Presenting to Ed with acute (onset within 7 days) abdominal,
back, flank, or musculoskeletal pain
Rated pain a score of 5 or more on standard 0-10 NRS
Attending physician determined opioid analgesia is needed

Pregnancy
Breastfeeding
Altered mental status
Allergy to morphine or
ketamine
Weight < 46 kg or > 115 kg
Systolic blood pressure < 90 or
> 180 mmHg
Heart rate < 50 or > 150 bpm
Respiratory rate < 10 or > 30
bpm
History of acute head or eye
injury
History of seizure
History of intracranial
hypertension
History of chronic pain
History of hepatic or renal
insufficiency
History of alcohol or drug
abuse
History of psychiatric illness
Opioid use within last 4 hours

Study Results
Patients in both groups showed significant reductions in NRS pain scores at 15 minutes (1.0) and 30 minutes (0.2), but no statistically significant difference was detected between the
groups. The changes in NRS pain scores for each group from baseline to 30 minutes showed a
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similar pattern of decline. More patients in the ketamine group experienced a complete resolution
of pain (NRS=0) at 15 minutes than patients in the morphine group; however, the difference had
dissipated at the 30-minute mark (Table 6). There was no statistically significant difference in
the use of rescue fentanyl at 30 and 60 minutes between the groups, but the ketamine group
required significantly more rescue fentanyl at the 120-minute mark.
No serious or life-threatening adverse events occurred with either medication. More
patients in the ketamine group reported minor adverse effects immediately after medication
administration and at the 15-minute mark when compared to the morphine group, but the
difference equalized at the 30 minutes. The most common minor adverse effects reported in both
groups were dizziness and nausea. Neither group experienced any significant change to vital
signs that were concerning or required intervention.

Dakoda Farrington & Amber Knowlton 12
Table 6. Pain trends overtime in study 3.10
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Study Critique
Strengths include design, study location, and similar group demographics. The study
directly compared morphine to ketamine for analgesia with a double-blinded, randomized control
trial. The sample population was selected at a large community teaching hospital with a highly
utilized ED, so the sample is potentially diverse. Confounding variables were reduced since the
groups were similar regarding demographic characteristics and baseline vital signs, pain scores,
and chief complaint.
Alternatively, some weaknesses were small sample size, the use of convenience
sampling, and participant inclusion was partially subjective. The use of convenience sampling
can allow for sampling bias, so the sample may not be representative of the entire population.
Inclusion was determined in part by the on-duty, attending physician’s subjective opinion on the
patient’s need for opioid analgesia.
DISCUSSION
Acute, moderate to severe pain in the ED is most commonly managed with IV opioids.
However, a current shortage of IV opioids is creating a demand for other options. Ketamine has
been used as a dissociative general anesthetic since the 1970s and current research has been
focused on ketamine utilization for safe and effective acute pain management.
An overview of the three studies is provided (Table 7). The Miller et al and Motov et al
studies are similar with small sample populations, similar pain characteristics, and the same drug
dosage. Mahshidfar et al had the advantage of a large population size, although the patient
population was trauma patients outside of the United States. All three studies used the NRS for
quantifying pain scores and utilized double-blinding procedure.
Table 7. Overview of studies
Miller, et al
Patients, n
45
Population
18-59 year olds
Acute abdominal,
flank, low back, or
extremity pain
Location
Military level 1
trauma center ED.
Uniformed military
(20%) and civilians
(80%)
Primary interest
Maximum change in
NRS pain score as
compared to baseline
Dosages
0.3 mg/kg LDK, IV
0.1 mg/kg MOR, IV
Blinding
Yes
Other outcomes
Adverse events, vital
measured
signs, & provider
satisfaction

Mahshidfar, et al
332
18-70 year olds
Trauma patients
2 university teaching
hospital EDs in
Tehran, Iran
Change in NRS pain
scores from baseline
over time
0.2 mg/kg LDK, IV
0.1 mg/kg MOR, IV
Yes
Adverse events, vital
signs, & patient
satisfaction

Motov, et al
90
18-55 year olds
Acute abdominal,
back, flank, or
musculoskeletal pain
711-bed community
teaching hospital ED

NRS pain score
reduction after 30
minutes
0.3 mg/kg LDK, IV
0.1 mg/kg MOR, IV
Yes
Adverse events, vital
signs, & fentanyl
rescue
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The primary outcome of the studies was pain reduction in ketamine versus morphine. All
three studies showed effective pain relief in the first 20 minutes without a statistically significant
difference between the treatment groups. The LDK group demonstrated an initial decrease in
pain scores followed by an increase after 30 minutes, whereas the MOR group showed a steady
decline in pain scores over time (Table 8). Specifically, in the Miller et al study, the maximum
reduction in pain score for the LDK group was seen immediately after infusion completion and
was sustained for only 5 to 10 minutes. In the MOR group, a steady decline in pain scores was
seen with a maximum reduction reached at 100 minutes post-infusion.
The short duration of ketamine’s analgesic effect likely led to the increased rate of
subsequent doses in the Miller et al and Mahshidfar et al studies and increased rescue fentanyl
use at 120 minutes in the Motov et al study. Miller et al observed repeat dosing for LDK (54%)
versus MOR (38%) although the difference was not statistically significant. In the ketamine
group, 25% of the patients did not complete the entire 120 minutes of data collection due to
requesting a third dose versus the 14% of patients excluded in the morphine arm due to
requesting a third dose. Mahshidfar et al study revealed a statistically significant difference
between the groups requesting an additional dose of analgesia, 34% in the ketamine group and
10% in the MOR group. Motov et al showed no statistically significant difference in the use of
rescue fentanyl at 30 and 60 minutes between the groups, but the ketamine group required
significantly more rescue fentanyl at the 120-minute mark (17% difference).
Table 8. Overview of pain scores over time
Baseline T5 T10 T15 T20 T30 T60 T100 T120
Miller et al
Ketamine
7.13
2.23 2.83
3.93
3.63 3.03 3.53
Morphine
7.14
4.14 3.74
3.84
2.34 2.14 2.14
Mahshidfar et al
Ketamine
8.1
4.1
4.5 4.9
Morphine
8.4
4.0
3.8 3.2
Motov et al
Ketamine
8.6
3.2
4.1 4.8
3.9
Morphine
8.5
4.2
3.9 3.4
3.7
- Indicates that pain scores were not recorded at this time.
Secondary outcomes measured included adverse drug events, vital signs, and provider or
patient satisfaction. No serious or life-threatening side effects were observed in any of the
studies. All three studies showed no significant difference between the groups in the rate of
minor adverse events, such as nausea and dizziness (Table 9). Miller et al and Mahshidfar et al
showed the MOR group experienced a statistically significant decrease in oxygen saturation.
Miller et al also revealed the LDK group experienced more dysphoria and hallucinations. Motov
et al observed a statistically significant increase in adverse effects immediately post-injection and
at the 15-minute mark in the LDK group, but the difference between the groups equalized at 30
minutes.
Miller et al found both drugs scored similarly with providers and nurses. The median
nursing satisfaction score was 4 (somewhat satisfied) for LDK and 5 (very satisfied) for MOR,
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but the difference was not statistically significant. Mahshidfar et al showed a greater patient
satisfaction score in the morphine group one-hour post-injection.
Table 9. Overview of adverse drug event rates
Decrease Dysphoria Hallucinations Flushing Nausea Dizziness
in
oxygen
saturation
Miller et al
Ketamine
0
16%
13%
13%
8%
Morphine
5%
0
0
10%
5%
Mahshidfar
et al
Ketamine
4%
4%
0
16%
34%
Morphine
18%
2%
36%
17%
32%
Motov et al
Ketamine
2%
13%
18%
Morphine
0
20%
13%
- Indicates that the adverse drug reaction was not analyzed.
CONCLUSION
In the treatment of acute pain, IV ketamine and IV morphine have a significant shortterm (15-30 minutes) reduction in pain scores; however, the effects of ketamine are
unsustainable without repeat dosing after 30 minutes. Morphine maintains a longer duration of
action without repeat dosing. Based on these results, ketamine does not appear to be an adequate
replacement for morphine in the management of acute pain in the ED.
Ketamine is still a promising alternative due to its similar short-term efficacy and safety
profile. It may be utilized in opioid-tolerant patients and in areas of IV opioid shortage. Since
ketamine is unable to sustain pain relief over the normal course of an ED stay, further research is
warranted for either higher doses of low-dose ketamine infused over a longer duration or the use
of adjunctive medications for ED management of acute pain.
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APPENDICES
Appendix 1: Example of a normal rating scale (NRS) pain score chart.11
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